Division of Liver Diseases, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Semin Liver Dis. 2011 Nov;31(4):347-55. doi: 10.1055/s-0031-1297924. Epub 2011 Dec 21.
Hepatocellular carcinoma (HCC) is a common cause of cancer-related mortality. The worldwide incidence of HCC and the hepatitis C virus (HCV) has increased over several decades suggesting an etiologic link. Progress has been made recently in several fields related specifically to HCV and HCC. The epidemiology has been better characterized, surveillance and treatment programs have been instituted, and data have emerged detailing the effect of other risk factors for HCC in patients with HCV. Studies of HCV-related HCC suggest differences in oncogenic potential according to genotype and mutations in the viral sequence. These same mutations are associated with interferon treatment failure, insulin resistance, and expression of HCV minicore proteins. These viral mutations provide a focus for investigations into the molecular basis of HCV-related oncogenesis, which may lead to improved diagnostic tests for early (curable) HCC and to interventions to prevent, and/or greatly retard, the oncogenic process.
肝细胞癌(HCC)是癌症相关死亡的常见原因。几十年来,全球范围内 HCC 和丙型肝炎病毒(HCV)的发病率一直在上升,这表明两者之间存在病因联系。最近在与 HCV 和 HCC 相关的几个特定领域取得了进展。流行病学得到了更好的描述,监测和治疗计划已经实施,并且出现了详细描述 HCV 患者中其他 HCC 危险因素的影响的数据。HCV 相关 HCC 的研究表明,根据基因型和病毒序列突变,致癌潜力存在差异。这些相同的突变与干扰素治疗失败、胰岛素抵抗和 HCV 微小核心蛋白的表达有关。这些病毒突变为研究 HCV 相关致癌作用的分子基础提供了重点,这可能导致开发出用于早期(可治愈)HCC 的改进诊断测试,以及预防和/或大大延缓致癌过程的干预措施。